Arcus Biosciences to Participate in Two Upcoming Investor Conferences

Rhea-AI Impact

(Neutral)

Rhea-AI Sentiment

(Neutral)

Tags

conferences

02/26/2026 - 04:05 PM

HAYWARD, Calif.--(BUSINESS WIRE)-- Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer and inflammatory and autoimmune diseases, announced that its management team will participate in the following upcoming investor conferences in March:

Leerink Global Healthcare Conference 2026
Date: Monday, March 9^th, 2026
Location: Miami, FL
Format: Fireside chat & 1x1 meetings
Time: 11:20 a.m. ET

Barclays 28^th Annual Global Healthcare Conference
Date: Tuesday, March 10^th, 2026
Location: Miami Beach, FL
Format: 1x1 meetings

A live webcast of the fireside chat will be available by visiting the “Investors & Media” section of the Arcus Biosciences website at www.arcusbio.com. A replay will be available following the live event.

About Arcus Biosciences

Arcus Biosciences is a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules for the treatment of cancer and inflammatory and autoimmune diseases. In partnership with industry collaborators, patients and physicians around the world, Arcus is expediting the development of its late-stage portfolio of first- and/or best-in-class medicines against well-characterized biological targets and pathways and studying novel, biology-driven combinations that have the potential to help people with cancer live longer. Founded in 2015, the company has advanced multiple investigational medicines into registrational clinical trials including casdatifan, a HIF-2a inhibitor for clear cell renal cell carcinoma, and quemliclustat, a small-molecule CD73 inhibitor for pancreatic cancer. For more information about Arcus Biosciences’ clinical and preclinical programs, please visit www.arcusbio.com.